TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01924481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No theobromine
Study: NCT01916967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, given orally, once daily in the evening for 2 weeks
Study: NCT02554851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human Epidermal Growth Factor (rhEGF)
Description: The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
Study: NCT01309308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sweeping the membranes
Description: The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No sweeping group
Description: Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
Study: NCT04167722

Intervention type: PROCEDURE
Intervention: Robotic Radical Prostatectomy
Description: Routine NHS Radical Prostatectomy

Intervention type: PROCEDURE
Intervention: Robotic Radical Prostatectomy
Description: Routine NHS Radical Prostatectomy
Study: NCT02702063

Intervention type: OTHER
Group type: OTHER
Intervention: passive leg raising test
Description: Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
Study: NCT00998959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction and Psychoeducation
Description: Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducation
Description: Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT02702063

Intervention type: PROCEDURE
Group type: OTHER
Intervention: right heart catheterisation
Description: CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC

Intervention type: OTHER
Group type: OTHER
Intervention: TTE vs. EC + calibration group
Description: Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
Study: NCT03024437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously every 3 weeks at 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously every 3 weeks at 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given intravenously every 3 weeks at 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT06275581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ketac Universal Aplicap Glass Ionomer Restorative (3M) (test group)
Description: Ketac Universal Aplicap Glass Ionomer Restorative (test group) was applied in one cavity of the patient, randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth. This material does not require a cavity conditioning step prior to restoration placement.
Study: NCT06275581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group)
Description: Ketac Molar Quick Aplicap Glass Ionomer Restorative (control group) was applied in the other cavity of the patient,randomized allocated, in a stress bearing Class II restoration when the isthmus was less than half of the intercuspal distance and with at least one occlusal contact on enamel of the restored tooth.
Study: NCT02374515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoCuff-assisted colonoscopy
Description: Adenoma detection rate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Study: NCT04223232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-MD1003
Description: single oral dose of 100mg \[14C\]-MD1003
Study: NCT02567201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological evaluation
Description: electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological evaluation of patients
Description: electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
Study: NCT04061980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06138093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing device
Description: Intratracheal tracheostomy sealing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No device
Description: Open tracheostomy wound
Study: NCT03860142

Intervention type: BEHAVIORAL
Intervention: Archet scale
Description: Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale

Intervention type: BEHAVIORAL
Intervention: Archet scale
Description: Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
Study: NCT03775161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-LAP™ System
Description: Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
Study: NCT02639156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES LONDON
Description: AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
Study: NCT00606827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline
Description: Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
Study: NCT02355496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Displaying medicare fee data
Description: Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
Study: NCT00586846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 120 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 12g/m\^2
Study: NCT05067959

Intervention type: BIOLOGICAL
Intervention: Covid-19 vaccine
Description: blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine

Intervention type: BIOLOGICAL
Intervention: Covid-19 vaccine
Description: blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine
Study: NCT02862054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: splenectomy
Study: NCT03318120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
Study: NCT00647413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bio-chemical feedback and expert system intervention ETS
Description: Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants
Study: NCT03353272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Education and Restructuring of Cognitions
Description: This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
Study: NCT00582790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
Study: NCT03570255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Neo SpO2
Description: All subjects are enrolled in the experimental group and receive the RD SET Neo SpO2 sensor.
Study: NCT00790062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: See arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arms
Study: NCT00874796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: Taken as one capsule by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: Taken as one capsule by mouth once daily
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT00874796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
Study: NCT01445756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; no topical lidocaine administered
Study: NCT02636413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gaxilose
Description: After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
Study: NCT02173184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gynevac
Description: 1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
Study: NCT00486174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue
Description: 2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
Study: NCT04082559

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Antibiotics treatment
Description: Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Antibiotics treatment
Description: Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Combination therapy (Antibiotics + diet)
Description: Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
Study: NCT02636413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactose
Description: After lactose administration, expired hydrogen measurement at pre-specified intervals.
Study: NCT01781338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT02638298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevana Dressing
Description: negative pressure wound therapy (NPWT) dressing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dry Gauze Dressing
Description: Standard Dry Gauze Dressing
Study: NCT04644861

Intervention type: OTHER
Group type: OTHER
Intervention: Program of adapted physical activity
Description: 3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
Study: NCT04082559

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Combination therapy (Antibiotics + diet)
Description: Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study

Intervention type: OTHER
Group type: OTHER
Intervention: Arm 3- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study
Study: NCT00608335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study: NCT01369615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride controlled-release tablets
Description: Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT03409718

Intervention type: DEVICE
Intervention: Biomet Comprehensive Shoulder System
Description: Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform